Evidence map›Paper›PMID 33196691›Full record

ArticleOncotarget2020

KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma.

Tyler S McCann, Janet K Parrish, Joseph Hsieh, Marybeth Sechler, Lays M Sobral, Chelsea Self, Kenneth L Jones, Andrew Goodspeed, James C Costello, Paul Jedlicka

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Cancers · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tyler S McCannDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Janet K ParrishDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Joseph HsiehDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Marybeth SechlerDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Lays M SobralDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Chelsea SelfDepartment of Pediatrics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Kenneth L JonesDepartment of Pediatrics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Andrew GoodspeedDepartment of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
James C CostelloDepartment of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Paul JedlickaDepartment of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
University of Colorado Cancer Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Medical Scientist Training ProgramT32GM008497 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI WILSON, CARA C. · 1993 to 2022
$15.2M
Training Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5M
Mechanism of tumor promotion by the H3K9 histone demethylase KDM3A in Ewing Sarcoma.R01CA183874 · NCI · UNIVERSITY OF COLORADO DENVER · PI JEDLICKA, PAUL · 2015 to 2019
$1.8M
The histone demethylase KDM3A upregulates MCAM to promote Ewing Sarcoma metastasisF31CA203053 · NCI · UNIVERSITY OF COLORADO DENVER · PI LUPO, MARYBETH SECHLER · 2016 to 2017
$46k
NCI NIH HHS F31 CA203053NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA183874NCI NIH HHS T32 CA190216NIGMS NIH HHS T32 GM008497
6 · The paper itself

Abstract

Ewing sarcoma is an aggressive malignant neoplasm with high propensity for metastasis and poor clinical outcomes. The EWS/Fli1 oncofusion is the disease driver in > 90% of cases, but presents a difficult therapeutic target. Moreover, EWS/Fli1 plays a complex role in disease progression, with inhibitory effects on critical steps of metastasis. Like many other pediatric cancers, Ewing sarcoma is a disease marked by epigenetic dysregulation. Epigenetic mechanisms present alternative targeting opportunities, but their contributions to Ewing sarcoma metastasis and disease progression remain poorly understood. Here, we show that the epigenetic regulators KDM5A and PHF2 promote growth and metastatic properties in Ewing sarcoma, and, strikingly, activate expression many pro-metastatic genes repressed by EWS/Fli1. These genes include L1CAM, which is associated with adverse outcomes in Ewing sarcoma, and promotes migratory and invasive properties. KDM5A and PHF2 retain their growth promoting effects in more metastatically potent EWS/Fli1

Indexed as

epigeneticsEwing sarcomaJumonji-domain histone demethylasemetastasis

Identifiers

PMID33196691
PMCPMC7597412
OpenAlexW3096589650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.